Breast cancer cells could modify the surrounding microenvironment and thereby escape the immune system.37 Compromised immunity is a major issue in breast cancer therapy: the patients receiving adjuvant therapy with doxorubicin and cyclophosphamide are exposed to high risk of grade-3 infection due to the lower mannose-binding lectin 2 expression in their body.38 Supplementation of MBP during anticancer therapy is one of strategies in immunotherapy39 and Abmb could be developed for that purpose. This evidence concerns the gene LMAN2 and breast cancer.